Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

480

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: Erbitux (Cetuximab)
DRUG: Bevacizumab
DRUG: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
DRUG: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Sponsor

University of Campania Luigi Vanvitelli